Clinical trials: Glucagon
Type 1 Diabetes
Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1
The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.
- Trial name
- NCT05960565
- Testing
- Glucagon
- Where
- Norway
- Volunteers
- 9 people
- Sponsor
- St. Olavs Hospital
Common Cold
A Study of Nasal Glucagon in Participants With a Common Cold
The main purpose of this study is to evaluate the safety of nasal glucagon (NG) in participants with a common cold, some of whom will also take a nasal decongestant.
- Trial name
- NCT02778100
- Testing
- Nasal Glucagon, Oxymetazoline
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Adults Growth Hormone Deficiency.
Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
Hypothesis: Pegvisomant combined with the glucagon stimulation test (GST) can improve the accuracy of this test when used to diagnose adult GH and cortisol (steroid hormone)insufficiency.
- Trial name
- NCT01804413
- Testing
- Pegvisomant, Regular insulin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Oregon Health and Science University
Environmental Enteric Dysfunction
Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)
The goal of this clinical trial is to learn whether teduglutide, a medicine that helps the intestine heal, can improve environmental enteric dysfunction in undernourished women aged 18 to 35 years living in urban slums of Dhaka.
- Trial name
- GAME (NCT07537686)
- Testing
- Teduglutide 0.05 dose
- Volunteers
- 55 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Obesity, Overweight
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose…
- Trial name
- NCT07628127
- Testing
- VRB-103, VRB-101
- Where
- 3 sites in Australia
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Verdiva Bio Dev Limited
Type 1 Diabetes Mellitus With Hypoglycemia
A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes
This is a single center, double-blind, randomized trial in subjects with type 1 diabetes mellitus applying an adaptive design approach.
- Trial name
- NCT04712266
- Testing
- Glucagon, Insulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abvance Therapeutics
Glucose Metabolism Disorders
The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.
- Trial name
- NCT03246451
- Testing
- Metformin, Saline, Exendin (9-39)
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists.
- Trial name
- NCT07846956
- Testing
- GLP-1 Receptor Agonist Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul Saglik Bilimleri University
Myocardial Injury
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery.
- Trial name
- GLUMINS (NCT06324461)
- Testing
- Dulaglutide 0.75mg subcutaneous injection
- Where
- 3 sites in China
- Volunteers
- 372 people
- Sponsor
- The University of Hong Kong
Cystic Fibrosis-related Diabetes
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children…
- Trial name
- NCT03258853
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Coronary Angiography, Glucagon-like Peptide-1
Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction
GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects.
- Trial name
- NCT03129594
- Testing
- plasma glucagon-like peptide-1 levels
- Volunteers
- 709 people
- Sponsor
- Chinese PLA General Hospital
Type 2 Diabetes
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
- Trial name
- NCT05694741
- Testing
- AZD0186
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes, Heart Failure
The Effects of Neprilysin on Glucagon-like Peptide-1
In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor
- Trial name
- NEP (NCT03717688)
- Testing
- Entresto, Sitagliptin 100mg
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Diabetes Mellitus, Type 1, Endothelial Dysfunction
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e.
- Trial name
- MCD-1 (NCT05478707)
- Testing
- Dulaglutide
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- AdventHealth Translational Research Institute
Healthy Subjects, Obesity
Glucagon Modulation of Ghrelin Secretion
As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hormone (GH)…
- Conditions
- Healthy Subjects, Obesity, Diabetes Mellitus, Type 1
- Trial name
- NCT00929812
- Testing
- Glucagon hydrochloride (GlucaGen®), NaCl 0.9%
- Where
- Germany
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Weight Loss
High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)
The primary objective of this study is to examine the effects of a high-protein diet (HP) paired with resistance training (RT) compared with a HP diet alone, on skeletal muscle mass (SMM) volume of the (a) quadriceps and (b)…
- Trial name
- NCT07700030
- Testing
- High protein diet, Resistance Training (RT) Programs
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Type 1 Diabetes Mellitus
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
This project is part of several studies exploring situations, where glucagon potential has lesser glucose elevating effect. Exercise can be one of these situations as exercise may reduce liver glycogen depots.
- Trial name
- NCT02882737
- Testing
- Glucagon before exercise, Glucagon after exercise, Glucagon after resting
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Hvidovre University Hospital
Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on clinical outcomes and metabolic parameters in a double-blind…
- Trial name
- ECHO (NCT02664441)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Seattle Children's Hospital
Postural Orthostatic Tachycardia Syndrome (POTS), Healthy
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in…
- Trial name
- GA22 (NCT07019519)
- Testing
- GIPR antagonist, GLP-1R antagonist, CCK agonist
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Intestinal Failure, Short Bowel Syndrome
Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure
This protocol outlines a randomized,open label trial examining the safety, pharmacology and efficacy of Glucagon like peptide 2 (GLP-2) in infants and children with intestinal failure.
- Trial name
- GLP-2-01 (NCT01573286)
- Testing
- Glucagon-Like Peptide 2, Glucagon like peptide-2
- Where
- 4 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Alberta Children's Hospital